Our clinical trials page gives a summary of current and recent vitiligo clinical trials, along with links to further information.

This study investigates why some areas of the body respond better to vitiligo treatments than others. While regions like the face and neck often show significant repigmentation, areas such as the hands, feet, and joints remain more resistant. Researchers believe that specific factors in the skin may inhibit the function and migration of melanocytes (pigment-producing cells). By analyzing skin samples from vitiligo patients and healthy volunteers, this study aims to identify these factors and improve treatment approaches for difficult-to-repigment areas.

Status: Open for Recruitment
Sponsor: Centre Hospitalier Universitaire de Nice
Identifier: NCT06068218
Summary: This study examines why certain body areas respond differently to vitiligo treatments by analyzing skin samples from patients and healthy volunteers. Researchers aim to identify inhibitory factors affecting melanocyte function and improve treatment strategies.

Learn more: visit Clinicaltrials.gov

This Phase II study aims to evaluate the effectiveness and safety of combining ANIFROLUMAB, an intravenous medication administered at 300mg every four weeks, with narrowband UVB TL01 phototherapy in adults with progressive non- segmental vitiligo. The study involves 48 participants who will be randomly assigned to receive either ANIFROLUMAB or a placebo, in conjunction with phototherapy. The treatment period includes ANIFROLUMAB or placebo infusions once a month for 36 weeks, with phototherapy sessions conducted twice weekly for 24 weeks, starting 12 weeks after the initial infusion. The primary goal is to assess the efficacy and tolerance of this combined treatment approach.

Status: Open for Recruitment
Sponsor: University Hospital of Bordeaux
Identifier: NCT05917561
Summary: This Phase II randomized, double-blind study evaluates the efficacy and safety of combining ANIFROLUMAB with narrowband UVB phototherapy in adults with progressive non-segmental vitiligo. Participants will receive monthly infusions of ANIFROLUMAB or placebo for 36 weeks, with phototherapy sessions twice weekly for 24 weeks, starting 12 weeks after the first infusion.

Learn more: visit Clinicaltrials.gov

This study aims to assess the effectiveness and safety of povorcitinib, an oral medication, in adults with nonsegmental vitiligo. Participants will receive either povorcitinib or a placebo to evaluate its impact on repigmentation and disease progression. The trial is currently recruiting participants across multiple locations in
the UK, including Ipswich, Leicester, Nottingham, Walsall, and London.

Status: Active, Not Recruiting
Sponsor: Incyte Corporation
Identifier: NCT05794127
Summary: This trial evaluates the efficacy and safety of povorcitinib, an oral tablet, in adults with nonsegmental vitiligo. Participants will be randomly assigned to receive either povorcitinib or a placebo to determine the treatment’s impact on skin repigmentation and disease progression.

Learn more: Visit ClinicalTrials.gov or Vitiligosociety.org

This Phase 3 study evaluates the safety and efficacy of upadacitinib, an oral Janus kinase (JAK) inhibitor, in treating non-segmental vitiligo in both adults and adolescents. Participants will be randomly assigned to receive either upadacitinib or a placebo once daily for 48 weeks. The trial aims to assess the proportion of participants achieving a ≥75% improvement in the Total Vitiligo Area Scoring Index (T-VASI) and monitor adverse events throughout the study period.

Status: Active, Not Recruiting
Sponsor: AbbVie
Identifier: NCT06118411
Summary: This Phase 3 study examines the safety and effectiveness of upadacitinib in treating non-segmental vitiligo, with participants receiving either upadacitinib or a placebo for 48 weeks. The primary goal is to evaluate the proportion of participants achieving a ≥75% improvement in the T-VASI.

Learn more: Visit ClinicalTrials.gov or Vitiligosociety.org

This Phase III clinical trial evaluates the efficacy and safety of afamelanotide (SCENESSE®) in combination with narrowband ultraviolet B (NB-UVB) light therapy compared to NB-UVB alone in treating vitiligo. Afamelanotide, an analogue of the natural hormone α-MSH, stimulates melanin production, potentially enhancing repigmentation in vitiligo patients. The study aims to determine if this combination therapy can improve repigmentation and assess the duration of maintained pigmentation post-treatment.

Status: Open for Recruitment
Sponsor: CLINUVEL Pharmaceuticals Ltd
Identifier: [NCT Identifier not provided]
Summary: This study involves approximately 200 participants aged 12 and older with Fitzpatrick skin types IV–VI. Participants will be randomized into two groups: one receiving afamelanotide implants combined with NB-UVB therapy, and the other receiving NB-UVB therapy alone. The trial includes a screening period of up to one month, a five-month treatment phase, and a six-month follow-up period. The primary objectives are to evaluate the improvement in repigmentation and the safety of the combined treatment.

Learn more: Visit ClinicalTrials.gov or Vitiligosociety.org

This Phase 3 study investigates the efficacy and safety of deucravacitinib, a TYK2 inhibitor, in treating generalized vitiligo. The trial aims to stop depigmentation and enhance repigmentation by targeting the IFN type I response and IL12. Deucravacitinib has demonstrated effectiveness in psoriasis and may improve repigmentation when combined with narrowband UVB (NB-UVB) therapy. Participants will receive either deucravacitinib or a placebo for 24 weeks, followed by re-randomization to assess the combination of deucravacitinib with NB-UVB therapy. The primary objective is to measure the proportion of patients achieving VITIL-IA 50 at Week 24.

Status: Open for Recruitment
Sponsor: Centre Hospitalier Universitaire de Nice
Identifier: NCT06327321
Summary: This Phase 3 study examines the impact of deucravacitinib on halting vitiligo progression and promoting repigmentation. Participants will receive deucravacitinib or a placebo for 24 weeks before re-randomization to evaluate the effects of combining it with NB-UVB therapy. The study will include six visits over 48 weeks, with optional skin biopsies and blood sample collections at multiple time points.

Learn more: Visit ClinicalTrials.gov

This study investigates the level and functionality of circulating functional mitochondria (CFM) in the serum of vitiligo patients compared to healthy controls and individuals with other skin conditions. The study aims to assess mitochondrial involvement in vitiligo pathogenesis. Participants include patients with non-segmental vitiligo, atopic dermatitis, psoriasis, and alopecia areata, as well as first-degree relatives of vitiligo patients. Blood samples are collected for analysis.

Status: Active, Not Recruiting
Sponsor: Centre Hospitalier Universitaire de Nice
Identifier: NCT05525741
Summary: This study examines the role of circulating functional mitochondria (CFM) in vitiligo, comparing their levels and functionality to those in healthy individuals and patients with related skin conditions. Blood samples are collected from participants to analyze mitochondrial function and potential links to vitiligo pathogenesis.

Learn more: Visit ClinicalTrials.gov

This Phase 2 study evaluates the effectiveness of epidermal cell suspension grafting followed by topical 1.5% ruxolitinib cream in promoting repigmentation in vitiligo-resistant areas. Participants received grafting on both sides of the body, with one side treated with ruxolitinib and the other with a placebo for three months. After this period, both sides were treated with ruxolitinib for an additional three months. The primary outcome measure is repigmentation of the target area at three and six months, assessed using Image J software.

Status: Completed
Sponsor: Centre Hospitalier Universitaire de Nice
Identifier: NCT05872477
Summary: This study investigated the efficacy of epidermal cell suspension grafting combined with topical ruxolitinib in treating vitiligo lesions resistant to conventional therapies. A randomized, intra-individual comparison was conducted, with one side of the body receiving ruxolitinib and the other a placebo for three months, followed by
ruxolitinib treatment on both sides for an additional three months. The primary outcome was repigmentation of the treated areas, with a ≥50% improvement considered successful.

Learn more: Visit ClinicalTrials.gov

This Phase 2 open-label study evaluates the safety and efficacy of ruxolitinib 1.5% cream in treating genital vitiligo. Participants with non-segmental vitiligo involving the genital area apply the cream twice daily to affected areas (up to 10% body surface area) for 48 weeks. The primary outcome measures include the proportion of participants achieving a Vitiligo Noticeable Score (VNS) of 4 or 5, indicating significant improvement or resolution of depigmentation. Secondary outcomes assess treatment-emergent adverse events, physician-reported global vitiligo
assessment, changes in affected body surface area, and color-matching of repigmented skin.

Status: Active, Not Recruiting
Sponsor: Incyte Corporation
Identifier: NCT05750823
Summary: This Phase 2 study investigates the use of ruxolitinib cream in participants with non-segmental vitiligo affecting the genital area. The treatment is applied twice daily for up to 48 weeks, with efficacy assessed through patient-reported outcomes, physician evaluations, and body surface area analysis. The study also monitors safety by tracking treatment-emergent adverse events.

Learn more: Visit ClinicalTrials.gov

This Phase 2a, multicenter, randomized, double-blind, placebo-controlled study evaluates the safety and efficacy of MK-6194 in adult participants with non- segmental vitiligo. The primary objective is to assess changes in the Facial Vitiligo Area Scoring Index (F-VASI) at Week 24 and monitor adverse events. Secondary outcomes include changes in the Total Vitiligo Area Scoring Index (T-VASI) and treatment discontinuation due to adverse events. Participants receive subcutaneous doses of MK-6194 or placebo, with an extension phase available for continued treatment.

Status: Active, Not Recruiting
Sponsor: Merck Sharp & Dohme LLC
Identifier: NCT06113328
Summary: This Phase 2a study investigates the efficacy and safety of MK-6194 in adult participants with non-segmental vitiligo. The study measures improvements in vitiligo severity and evaluates potential side effects. Treatment is administered via subcutaneous injection, with participants randomized into different dosing regimens
or placebo. The estimated study completion date is October 2025.

Learn more: Visit ClinicalTrials.gov or Vitiligosociety.org

Last updated: February 2025